GlaxoSmithKline doubles down on Vir pact, throwing in $345M upfront to go beyond COVID-19
Last year, Big Pharma GlaxoSmithKline and George Scangos’ biotech Vir joined forces against COVID-19. Now, the pair is turning its...
GlaxoSmithKline doubles down on Vir pact, throwing in $345M upfront to go beyond COVID-19
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
Sana snags $587.5M IPO to catapult cell therapies into the clinic
Gilead Sciences and Gritstone Announce Collaboration For HIV Cure
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID
Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’
Top Life Sciences Startups to Watch in 2021
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Therapy